company background image
MNKD

MannKind NasdaqGM:MNKD Stock Report

Last Price

US$3.96

Market Cap

US$1.0b

7D

11.2%

1Y

-25.1%

Updated

27 Jun, 2022

Data

Company Financials +
MNKD fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

MNKD Stock Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.

MannKind Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MannKind
Historical stock prices
Current Share PriceUS$3.96
52 Week HighUS$5.53
52 Week LowUS$2.49
Beta1.93
1 Month Change-10.81%
3 Month Change3.94%
1 Year Change-25.14%
3 Year Change253.57%
5 Year Change197.74%
Change since IPO-94.38%

Recent News & Updates

Shareholder Returns

MNKDUS BiotechsUS Market
7D11.2%10.3%6.3%
1Y-25.1%-24.5%-18.8%

Return vs Industry: MNKD matched the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: MNKD underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is MNKD's price volatile compared to industry and market?
MNKD volatility
MNKD Average Weekly Movement12.2%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: MNKD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MNKD's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991349Michael Castagnahttps://www.mannkindcorp.com

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.

MannKind Fundamentals Summary

How do MannKind's earnings and revenue compare to its market cap?
MNKD fundamental statistics
Market CapUS$1.00b
Earnings (TTM)-US$94.01m
Revenue (TTM)US$70.00m

14.3x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MNKD income statement (TTM)
RevenueUS$70.00m
Cost of RevenueUS$42.25m
Gross ProfitUS$27.75m
Other ExpensesUS$121.76m
Earnings-US$94.01m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.37
Gross Margin39.65%
Net Profit Margin-134.30%
Debt/Equity Ratio-121.4%

How did MNKD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MNKD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MNKD?

Other financial metrics that can be useful for relative valuation.

MNKD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue17.5x
Enterprise Value/EBITDA-19.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MNKD's PS Ratio compare to its peers?

MNKD PS Ratio vs Peers
The above table shows the PS ratio for MNKD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average26.6x
MRUS Merus
18.4x51.6%US$966.4m
EDIT Editas Medicine
34.7x47.3%US$894.6m
MORF Morphic Holding
45.8x63.7%US$866.4m
VCEL Vericel
7.7x21.5%US$1.2b
MNKD MannKind
14.3x35.0%US$1.0b

Price-To-Sales vs Peers: MNKD is good value based on its Price-To-Sales Ratio (14.3x) compared to the peer average (26.6x).


Price to Earnings Ratio vs Industry

How does MNKD's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: MNKD is expensive based on its Price-To-Sales Ratio (14.3x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is MNKD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MNKD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.3x
Fair PS Ratio7.8x

Price-To-Sales vs Fair Ratio: MNKD is expensive based on its Price-To-Sales Ratio (14.3x) compared to the estimated Fair Price-To-Sales Ratio (7.8x).


Share Price vs Fair Value

What is the Fair Price of MNKD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MNKD ($3.96) is trading below our estimate of fair value ($9.88)

Significantly Below Fair Value: MNKD is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MNKD's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is MannKind forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


68.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MNKD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MNKD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MNKD is expected to become profitable in the next 3 years.

Revenue vs Market: MNKD's revenue (35% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: MNKD's revenue (35% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MNKD's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has MannKind performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-20.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MNKD is currently unprofitable.

Growing Profit Margin: MNKD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MNKD is unprofitable, and losses have increased over the past 5 years at a rate of 20.5% per year.

Accelerating Growth: Unable to compare MNKD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MNKD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: MNKD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is MannKind's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MNKD has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MNKD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MNKD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MNKD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is MannKind current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MNKD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MNKD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MNKD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MNKD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MNKD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Michael Castagna (44 yo)

5.08yrs

Tenure

US$4,030,833

Compensation

Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD4.03M) is about average for companies of similar size in the US market ($USD4.02M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MNKD's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: MNKD's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MannKind Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: MannKind Corporation
  • Ticker: MNKD
  • Exchange: NasdaqGM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.000b
  • Shares outstanding: 252.57m
  • Website: https://www.mannkindcorp.com

Number of Employees


Location

  • MannKind Corporation
  • 30930 Russell Ranch Road
  • Suite 300
  • Westlake Village
  • California
  • 91362
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.